Filing Flows › Harmony Biosciences Holdings (HRMY) › Stock forecast & fair value
Harmony Biosciences Holdings (HRMY) stock forecast and price target
Harmony Biosciences Holdings (HRMY) trades at $33.11. 12 analysts' median price target is $49.50 (+50%), from $30.00 to $70.00.
Harmony Biosciences Holdings' latest quarter
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for HRMY stock?
The median of 12 analysts' 12-month targets is $49.50, +50% from $33.11; the range is $30.00 to $70.00. The average rating is buy.
Does Harmony Biosciences Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is HRMY stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.